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Background
The usefulness of HIV envelope proteins for vaccine design
is widely accepted since the RV144 HIV-1 prime-boost
vaccine trial. It is assumed that a trimeric structure close to
the natural form of the HIV envelope is preferable.
Methods
We have expressed the soluble form of the HIV envelope
of the C/B’ strain 97/CN/54 in CHO cells. The produc-
tion process consisted of a large-scale fed-batch fermen-
tation, an antibody-based affinity chromatography plus
additional purifying steps. CN54gp140 was extensively
characterized for purity and identity. All glycosylation
sites were characterized by mass spectrometry. Immuno-
genicity and safety were evaluated in mice, rabbits, mini-
pigs, sheep as well as non-human primates. The antigen
was formulated for clinical phase I studies in Tris buffer
(MUCOVAC I, HIVIS07) in HEC gel (MUCOVAC I) as
well as chemically conjugated to hsp70 (MUVAPRED).
Results
The vaccine antigen candidate CN54gp140 proved to be
of high purity and long-term stability. The immune
response was strongest with i.m. application whereas the
mucosal routes (i.vag., i.n.) were less immunogenic.
Safety was demonstrated in animal models as well as in
the clinical phase I studies MUCOVAC I, MUVAPRED
and HIVIS07.
Conclusion
CN54gp140 is a highly immunogenic trimeric envelope
protein which can be manufactured in sufficient quality
and quantity for clinical application. It proved to be
immunogenic in several animal models. Finally, it is well
tolerated in several formulations and combinations in
humans.
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